micro-community-banner
Profile Image
  • Saved
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia - Current Atherosclerosis Reports

The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia - Current Atherosclerosis Reports

Source : https://link.springer.com/article/10.1007/s11883-022-01013-x

Purpose of Review Lifestyle modification is additive to lipid-lowering medications in the treatment of heterozygous familial hypercholesterolemia (HeFH), which does not respond sufficiently to statin therapy. While both are also...



Summary: Approvals for PCSK9 and ANGPTL3 inhibitors have expanded opportunities for children and adolescents with HeFH and HoFH to achieve lower LDL-C levels.

Profile Image
  • Saved
Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model - PubMed

Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35367164/

1 Specialty Pharmacy Services, Vanderbilt University Medical Center, 726 Melrose Avenue Nashville, TN 37211, United States. Electronic address: [email protected]. 2 Specialty Pharmacy Services, Vanderbilt University Medical Center, 726 Melrose Avenue...



Conclusions: High rates of persistence to PCSK9i were seen in patients receiving care within an integrated specialty pharmacy model compared with rates in previous studies, suggesting specialty pharmacists may play a role in mitigating many common reasons for PCSK9i non-persistence.

Profile Image
  • Saved
Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab - PubMed

Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35386132/

2021 Nov 29;4(3):347-349. doi: 10.1016/j.cjco.2021.11.009. 1 Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. 2 Robarts Research Institute, Schulich School of Medicine and Dentistry,...



Conclusion/Relevance: We describe an Ontario patient with HoFH who for 17 months has been treated with monthly infusions of evinacumab added to pre-existing statin, ezetimibe, and evolocumab therapy. Evinacumab in this HoFH patient was associated with markedly improved LDL-C levels and decreased frequency of apheresis.

Profile Image
  • Saved
Combining familial hypercholesterolemia and statin genetic studies as a strategy for the implementation of pharmacogenomics. A multidisciplinary approach - The Pharmacogenomics Journal

Combining familial hypercholesterolemia and statin genetic studies as a strategy for the implementation of pharmacogenomics. A multidisciplinary approach - The Pharmacogenomics Journal

Source : https://www.nature.com/articles/s41397-022-00274-8

The diagnostic process of familial hypercholesterolemia frequently involves the use of genetic studies. Patients are treated with lipid-lowering drugs, frequently statins. Although pharmacogenomic clinical practice guidelines focusing on genotype-based statin...



Conclusion: This implementation approach facilitates the incorporation of pharmacogenomic studies in clinical care practice, it does not add complexity nor additional steps to laboratory processes, and improves the pharmacotherapeutic process of patients.

Profile Image
  • Saved
Reduced cardiovascular risks in women with endometriosis or polycystic ovary syndrome carrying a common functional IGF1R variant - PubMed

Reduced cardiovascular risks in women with endometriosis or polycystic ovary syndrome carrying a common functional IGF1R variant - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35362533/

doi: 10.1093/humrep/deac059. Online ahead of print. 1 Buck Institute for Research on Aging, Novato, CA, USA. 2 Graduate Group in Biostatistics, University of California, Berkeley, School of Public Health, Berkeley,...



Relevance: These findings implicate systemic dysregulation of the insulin-like growth factor-1 axis in the development of HTN, HC and clinical CVD in endometriosis and PCOS, suggesting a common underlying pathogenetic mechanism.

Profile Image